Buzzberg Cup Live

H2 Non-Semiconductor Strategy! Why You Should Look at US Healthcare and Bio | Park Hyun-ji, Yeo Doeun, Heo Jaemu [Morning N Investment]

H2 Non-Semiconductor Strategy! Why You Should Look at US Healthcare and Bio | Park Hyunji, Yeo Doeun, Heo Jaemu [Morning N Investment]
Watch on YouTube ↗  |  July 02, 2026 at 02:20  |  26:49  |  3PRO TV (삼프로TV)
Speakers
Park Hyun-ji — Manager

Summary

ETF expert Park Hyun-ji discusses the rotation out of semiconductors into US healthcare and biotech for the second half. She highlights catalysts such as Medicare coverage for GLP-1 obesity drugs, a blockbuster patent cliff driving M&A, and AI in medicine. She recommends five Korean-listed ETFs spanning conservative to aggressive exposures, including a global biotech active ETF with European names.

  • Market rotation from semiconductors to other sectors creates opportunity in US healthcare and biotech.
  • GLP-1 obesity drug momentum and upcoming Medicare coverage provide a short-term catalyst.
  • Patent expirations on 200+ blockbuster drugs through 2030 will accelerate M&A in pharma/biotech.
  • AI integration (drug discovery, genomics, digital health) adds a long‑term growth theme in healthcare.
  • KODEX S&P500 Healthcare offers a conservative, defensive entry into the US healthcare rotation.
  • TIGER US Nasdaq Bio provides aggressive, IBB-like exposure for investors seeking faster upside.
  • KoAct US BioHealthcare Active targets event-driven M&A momentum with an active management approach.
  • OneQ US Medical AI is a concentrated, high‑risk ETF including Alphabet and Nvidia in AI healthcare.
  • Global Bio Active ETF diversifies into strong European biotech names alongside US holdings.
Ideas
Park Hyun-ji Manager 6:09
Rotation to US healthcare with GLP-1 catalyst
The ongoing rotation out of semiconductors and into other sectors is creating a window for US healthcare and biotech. Key catalysts include Medicare beginning to cover GLP-1 obesity treatments, a looming patent cliff on blockbuster drugs that will force big pharma to pursue M&A, and AI-driven innovation in drug development and medical devices. This combination of rotation flows and sector-specific momentum supports a bullish stance on US healthcare.
XLV MED
Park Hyun-ji Manager 11:36
Conservative ETF for US healthcare rotation
KODEX S&P500 Healthcare ETF offers a conservative, defensive way to play the US healthcare rotation. It holds large pharma, medical device, and healthcare service companies with low volatility, making it suitable for risk-averse investors who want near-term (1–2 month) exposure without excessive downside.
KODEX S&P500 Healthcare HIGH
Park Hyun-ji Manager 11:55
Aggressive Nasdaq biotech ETF for upside
TIGER US Nasdaq Bio ETF is an aggressive biotech vehicle similar to the US-listed IBB. It holds a mix of large and mid‑small biotech names with significant exposure to GLP-1 and other innovative pipelines, aiming for faster upside. It suits investors willing to accept higher volatility for greater return potential.
IBB MED
Park Hyun-ji Manager 12:04
Active ETF to ride biotech M&A wave
KoAct US BioHealthcare Active ETF is an active strategy designed to capture event-driven M&A momentum in biotech. With M&A volumes approaching 2018 highs and big pharma needing to replenish pipelines ahead of the patent cliff, an active manager can rotate into targets and catalyst events, offering a more dynamic exposure than a passive index.
KOBIO MED
Park Hyun-ji Manager 12:44
Concentrated AI healthcare ETF with big‑tech
OneQ US Medical AI ETF is a concentrated, high-risk vehicle focused on AI applications in healthcare, including digital health, genomics, and AI drug discovery. It holds only 15 names at 90% weight, with big‑tech contributors like Alphabet and Nvidia alongside pure‑play AI medical companies. The long‑term growth thesis benefits from accelerating AI integration in medicine, though volatility is very high.
OneQ US Medical AI MED
Park Hyun-ji Manager 23:24
Global biotech ETF includes European leaders
The unlisted ‘Global Bio Active’ ETF adds European biotech leaders (e.g., Novartis, Argenx, Teva) to US names, providing global diversification. European biotech has strong drug development infrastructure and often trades at different valuation cycles. Including this ETF captures a worldwide biotech opportunity beyond a US‑only approach.
Global Bio Active ETF MED
Up Next
23:35
300,000 Electronics', '2,500,000 Hynix' Finally Broken! Should We Consider Further Declines? | Park Ji-hoon, Yeo Do-eun, Heo Jae-mu [Morning N Investment]
3PRO TV (삼프로TV) · Jul 02
23:59
Semiconductor Strength Has Absolutely Not Broken, It's Just a Correction...How to Respond? | Kim Rok-ho, Hana Securities Research Center Team Leader [Double Up]
3PRO TV (삼프로TV) · Jul 02
15:07
The correction we wanted is here, should we enter Samsung Electronics and SK Hynix? Or materials, parts, and equipment? | Kim Taeyeon, Hana Securities Yongsan WM Center Manager [Double Crew]
3PRO TV (삼프로TV) · Jul 02
26:40
AI Semiconductor Peak Out? The Truth Behind Meta Shock That Caused Semiconductor Stock Price Crash / 5 Issues Shaking Today's Stock Market | Director Lee Ju-yeon
815 Money Talk (815머니톡) · Jul 02
40:29
Samsung Electronics breaks ₩30,000...Has a real bear market arrived? | Yoo Chang-hee, Yoostock CEO [Double Check]
3PRO TV (삼프로TV) · Jul 02

This 3PRO TV (삼프로TV) video, published July 02, 2026, features Park Hyun-ji discussing XLV, KODEX S&P500 Healthcare, IBB, KOBIO, OneQ US Medical AI, Global Bio Active ETF. 6 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Park Hyun-ji  · Tickers: XLV, KODEX S&P500 Healthcare, IBB, KOBIO, OneQ US Medical AI, Global Bio Active ETF